P-113 Association Between 25-Hydroxy Vitamin D and Risk of Cancer in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Abstract

BACKGROUND: Vitamin D deficiency has been associated with increased risk of cancer in patients with inflammatory bowel disease (IBD). Primary sclerosing cholangitis (PSC) is associated with increased risk of cancers in patients with IBD. The impact of Vitamin D deficiency in patients with PSC and IBD is not known. Our aim was to study the association of Vitamin D deficiency and the risk of cancers in patients with PSC-IBD. METHOD(S): Patients with PSC and IBD followed up at a single institution from 1985 to 2014 were included. The primary outcome was development of any cancer. Patients with 1 measurement of plasma 25 (OH) D were included in the analysis. We examined the association between plasma 25 (OH) D levels and the risk of any cancer after adjusting for other covariates. RESULT(S): We analyzed data from 188 patients with PSC-IBD and a mean plasma level of 25 (OH) D of 21.0 ng/mL. More than one-half of patients (96/188, 51.1%) had deficient levels of vitamin D (<20 ng/mL). During a median follow-up period of 10.4 years, 26 patients (13.8%) developed cancer (excluding non-melanoma skin cancer). The various cancers were colon cancer 15.4%, cholangiocarcinoma 15.4%, hepatocellular carcinoma 11.5%, gall bladder cancer 3.8%, breast cancer 3.8%, prostate cancer 11.5%, lung cancer 3.8%, bladder cancer 3.8%, lymphoproliferative cancer 7.7%, bone cancer 3.8%, and thyroid CA 15.4%. On multivariate analysis after controlling for age, sex, body mass index, and duration of Vitamin D supplementation, patients with vitamin D deficiency did not have an increased risk of cancer (adjusted odds ratio, 1.00; 95% confidence interval, 0.97- 1.03) compared with those with sufficient levels. (Table 1). CONCLUSION(S): In our study of PSC-IBD patients, Vitamin D deficiency was not associated with increased risk of cancers. (Table Presented).